VN
Vivek Naranbhai
Research areas: Medicine · Infectious Diseases · HIV Research and Treatment · SARS-CoV-2 and COVID-19 Research · Genetic Associations and Epidemiology
0000-0003-4281-8882
Employment
Employment history is unavailable.
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (123)
- Incidence of Reported Pseudoprogression on 18F‐FDG PET/CT in Metastatic Melanoma Patients Undergoing Immune Checkpoint Inhibitor Immunotherapy Save
- Mind the corner: Fillets in cryo-FIB lamella preparation to minimise sample loss caused by stress concentration and lamella breakage Save
- T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19 Save
- Revealing human mobility trends during the SARS-CoV-2 pandemic in Nigeria via a data-driven approach Save
- Setting up data science research in Africa and engagement of stakeholders Save
- Altered IL-6 signalling and risk of tuberculosis disease: a meta-analysis and Mendelian randomisation study Save
- Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2 Save
- Brief Report: Declining Rates of SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies Save
- Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer Save
- Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study Save
- Multi-ancestry meta-analysis of host genetic susceptibility to tuberculosis identifies shared genetic architecture Save
- Genetic variation that determines TAPBP expression levels associates with the course of malaria in an HLA allotype-dependent manner Save
- Germline variants associated with immunotherapy-related adverse events Save
- Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines Save
- T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals Save
- ACTR1A has pleiotropic effects on risk of leprosy, inflammatory bowel disease and atopy Save
- T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all prior infected and vaccinated individuals Save
- Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study Save
- Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer Save
- Association of Cutaneous Immune-Related Adverse Events with Increased Survival in Patients Treated with Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Therapy Save